X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (41) 41
humans (39) 39
hepacivirus - genetics (25) 25
genotype (24) 24
hepacivirus - drug effects (22) 22
hepatitis c virus (18) 18
hepatitis c, chronic - drug therapy (18) 18
viral nonstructural proteins - genetics (17) 17
virology (17) 17
female (16) 16
gastroenterology & hepatology (16) 16
male (16) 16
antiviral agents - therapeutic use (15) 15
treatment outcome (15) 15
sofosbuvir (14) 14
hepatitis c, chronic - virology (13) 13
middle aged (13) 13
viral nonstructural proteins - antagonists & inhibitors (13) 13
adult (12) 12
antiviral agents (12) 12
hepatitis c (12) 12
infectious diseases (12) 12
microbiology (12) 12
antiviral agents - administration & dosage (11) 11
drug resistance, viral (11) 11
in-vitro (11) 11
pharmacology & pharmacy (11) 11
replication (11) 11
uridine monophosphate - analogs & derivatives (11) 11
antiviral agents - pharmacology (10) 10
hepatitis c - virology (10) 10
telaprevir (10) 10
drug therapy, combination (9) 9
hepatitis c - drug therapy (9) 9
infection (9) 9
ledipasvir (9) 9
plus ribavirin (9) 9
ribavirin (9) 9
aged (8) 8
drug resistance, viral - genetics (8) 8
health aspects (8) 8
hepacivirus - classification (8) 8
hepatitis-c virus (8) 8
high-throughput nucleotide sequencing (8) 8
resistance (8) 8
benzimidazoles - administration & dosage (7) 7
benzimidazoles - therapeutic use (7) 7
care and treatment (7) 7
fluorenes - administration & dosage (7) 7
fluorenes - therapeutic use (7) 7
genotype 1 infection (7) 7
hcv (7) 7
hepacivirus - isolation & purification (7) 7
hepatitis (7) 7
uridine monophosphate - therapeutic use (7) 7
amino acid substitution (6) 6
antiviral activity (6) 6
genetic aspects (6) 6
infections (6) 6
interferon (6) 6
medical research (6) 6
mutation (6) 6
open-label (6) 6
sustained virologic response (6) 6
variants (6) 6
young adult (6) 6
antiretroviral drugs (5) 5
cell line (5) 5
clinical trials (5) 5
combination (5) 5
double-blind method (5) 5
gastroenterology and hepatology (5) 5
medicine, experimental (5) 5
patients (5) 5
phase-2 trial (5) 5
protease inhibitors (5) 5
proteases (5) 5
ribavirin - administration & dosage (5) 5
ribavirin - therapeutic use (5) 5
sequence analysis, dna (5) 5
therapy (5) 5
treatment-naive patients (5) 5
velpatasvir (5) 5
adolescent (4) 4
analysis (4) 4
antiviral agents - adverse effects (4) 4
benzimidazoles - pharmacology (4) 4
boceprevir (4) 4
cell line, tumor (4) 4
drug resistance (4) 4
genotype & phenotype (4) 4
genotypes (4) 4
hcv genotype 1 (4) 4
infectious disease (4) 4
sofosbuvir - therapeutic use (4) 4
subgenomic replicons (4) 4
uridine monophosphate - administration & dosage (4) 4
viral nonstructural proteins - metabolism (4) 4
virus diseases (4) 4
virus-infection (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
Journal Article
Journal Article
by Altshuler, David M and Durbin, Richard M and Abecasis, Gonçalo R and Bentley, David R and Chakravarti, Aravinda and Clark, Andrew G and Donnelly, Peter and Eichler, Evan E and Flicek, Paul and Gabriel, Stacey B and Gibbs, Richard A and Green, Eric D and Hurles, Matthew E and Knoppers, Bartha M and Korbel, Jan O and Lander, Eric S and Lee, Charles and Lehrach, Hans and Mardis, Elaine R and Marth, Gabor T and McVean, Gil A and Nickerson, Deborah A and Schmidt, Jeanette P and Sherry, Stephen T and Wang, Jun and Wilson, Richard K and Dinh, Huyen and Kovar, Christie and Lee, Sandra and Lewis, Lora and Muzny, Donna and Reid, Jeff and Wang, Min and Fang, Xiaodong and Guo, Xiaosen and Jian, Min and Jiang, Hui and Jin, Xin and Li, Guoqing and Li, Jingxiang and Li, Yingrui and Li, Zhuo and Liu, Xiao and Lu, Yao and Ma, Xuedi and Su, Zhe and Tai, Shuaishuai and Tang, Meifang and Wang, Bo and Wang, Guangbiao and Wu, Honglong and Wu, Renhua and Yin, Ye and Zhang, Wenwei and Zhao, Jiao and Zhao, Meiru and Zheng, Xiaole and Zhou, Yan and Gupta, Namrata and Clarke, Laura and Leinonen, Rasko and Smith, Richard E and Zheng-Bradley, Xiangqun and Grocock, Russell and Humphray, Sean and James, Terena and Kingsbury, Zoya and Sudbrak, Ralf and Albrecht, Marcus W and Amstislavskiy, Vyacheslav S and Borodina, Tatiana A and Lienhard, Matthias and Mertes, Florian and Sultan, Marc and Timmermann, Bernd and Yaspo, Marie-Laure and Fulton, Lucinda and Fulton, Robert and Weinstock, George M and Balasubramaniam, Senduran and Burton, John and Danecek, Petr and Keane, Thomas M and Kolb-Kokocinski, Anja and McCarthy, Shane and Stalker, James and Quail, Michael and Davies, Christopher J and Gollub, Jeremy and Webster, Teresa and Wong, Brant and Zhan, Yiping and Auton, Adam and Yu, Fuli and Bainbridge, Matthew and Challis, Danny and Evani, Uday S and Lu, James and Nagaswamy, Uma and Sabo, Aniko and ... and 1000 Genomes Project Consortium and The 1000 Genomes Project Consortium
Nature, ISSN 0028-0836, 11/2012, Volume 491, Issue 7422, pp. 56 - 65
Journal Article